<DOC>
	<DOCNO>NCT02322866</DOCNO>
	<brief_summary>To evaluate efficacy safety approximate 1.5mg/kg/day dose oral sarecycline compare placebo treatment moderate severe facial acne vulgaris</brief_summary>
	<brief_title>Randomized , Double-blind , Placebo-controlled Study Evaluate Safety &amp; Efficacy Sarecycline Treatment Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Signed informed consent assent form Male/female , 9 45 year age , inclusive Body weight 33 136 kg , inclusive Facial acne vulgaris : 2050 inflammatory lesion ( papule , pustule nodule ) 30100 noninflammatory lesion ( open close comedo ) No 2 nodule IGA score moderate ( 3 ) severe ( 4 ) Negative urine pregnancy test baseline female childbearing potential Agrees use effective method contraception throughout study Refrain use acne medication medicate cleanser , avoid excessive sun exposure tan booth duration study Able fulfill requirement protocol , indicate willingness participate study agree study procedure ( include mandatory photography ) provide write informed consent/assent authorization disclose protected health information ( PHI ) Has dermatological condition face could interfere clinical evaluation Has history follow : Allergy tetracyclineclass antibiotic ingredient study drug Pseudomembranous colitis antibioticassociated colitis Treated type cancer within last 6 month Has know resistance tetracycline Has receive follow treatment within 12 week screening : Systemic retinoids Systemic corticosteroid Androgens/antiandrogenic therapy ( eg , anabolic steroid , spironolactone ) Nonmedicated procedure treatment acne ( eg , laser , light ThermaClear ) Has use acne affect treatment without appropriate washout period Has initiate hormonal contraceptive use within 12 week prior screen plan initiate switch hormonal contraceptive product study period Is pregnant , lactate plan pregnancy study period Has disorder cause hyperandrogenism include , limited polycystic ovary syndrome , adrenal ovarian tumor , Cushings disease congenital adrenal hyperplasia Has druginduced acne Has significant intercurrent illness , psychiatric disposition factor , opinion Investigator Medical Monitor , preclude participation study Is currently participate , participate within 30 day prior screen period investigational drug device study Has previously participate clinical trial involve use sarecycline Is judge Investigator unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acne</keyword>
</DOC>